Contributions
Abstract: EP1542
Type: ePoster
Abstract Category: Therapy - disease modifying - Others
Fingolimod is a drug approved for treatment of relapsing remitting multiple sclerosis (RRMS). Its main mechanism of action is the reduction of lymphocytes in blood. Our objective was to analyze the evolution of the lymphocytes levels during treatment with fingolimod and to determinate the correlation between those levels and infections or relapses.
Methods: A multicenter observational study was conducted. All patients with RRMS who started treatment with fingolimod were selected. Lymphocytes level was analyzed at baseline and at months 1, 3, 6, 12, 18 and 24 after treatment starting. The number of relapses and infections was also collected at all timepoints.
Results: 99 patients were included in the study. 62.6% were women, the mean age was 39.8±7.56 years, with 9.6±5.8 years of disease evolution, 1.4±1.4 relapses in the previous year and a median EDSS of 2±1.68. The mean of lymphocytes was 2225±908, 849±379, 836±440, 774±392, 718±312, 662±222 and 693±264 respectively on baseline and on months 1, 3, 6, 12, 18 and 24. We found a correlation between severity of lymphopenia and basal lymphocytes during the first 18 months (Pearson 0.552, p< 0.001 (month 1); 0.470, p< 0.001 (month 3); 0.418, p< 0.001 (month 6), 0.336, p=0.003 (month 12); 0.333, p=0.021 (month 18); 0.070, p=0.663 (month 24). We did not found a direct correlation between levels of lymphocytes and infections (Pearson 0.076, p=0.470, month 3; 0.086, p=0.425, month 6; -0.032, p=0.783, month 12; -0.289, p=0.049, month 18; -0.090, p= 0.569, month 24) or relapses (Pearson -0.061, p=0.558, month 3; -0.041, p=0.704, month 6; 0.21, p=0.029, month 12; 0.068, p=0.644, month 18; 0.051, p=0.773, month 24).
Conclusions: Fingolimod causes a significant decrement in lymphocytes from the first month and it becomes maximal on month 18. The lymphopenia is higher in patients with lower levels of lymphocytes in baseline. The severity of lymphopenia is not related with infections or relapses.
Disclosure:
E Costa Arpín has served as a speaker and member of a speakers bureau for Biogen Idec Inc, Merck Serono, and Genzyme Corporation. She also has received grants for clinical research from H. Lundbeck A/S.
A Pato Pato has served as a speaker and member of a speakers bureau for Biogen Idec Inc, Novartis Pharmaceutical Corporation, Almirall Prodesfarma, and Genzyme Corporation.
A Rodríguez Regal has served as a speaker or member of a speakers bureau for Almirall Prodesfarma, Biogen Idec Inc, Merck Serono, Novartis Pharmaceuticals Corporation, and Teva Pharmaceuticals.
MC Amigo has served as a speaker or member of a speakers bureau for Almirall Prodesfarma, Biogen Idec Inc, Merck Serono, Novartis Pharmaceuticals Corporation, and Teva Pharmaceuticals.
J Prieto González has served as an advisor, consultant, and speaker for Bayer HealthCare Pharmaceuticals, Biogen Idec Inc, Genzyme Corporation, Novartis Pharmaceuticals Corporation, Sanofi Aventis, and Teva Pharmaceuticals. He has also received grants for clinical research from Biogen Idec Inc and Novartis Pharmaceuticals Corporation.
Abstract: EP1542
Type: ePoster
Abstract Category: Therapy - disease modifying - Others
Fingolimod is a drug approved for treatment of relapsing remitting multiple sclerosis (RRMS). Its main mechanism of action is the reduction of lymphocytes in blood. Our objective was to analyze the evolution of the lymphocytes levels during treatment with fingolimod and to determinate the correlation between those levels and infections or relapses.
Methods: A multicenter observational study was conducted. All patients with RRMS who started treatment with fingolimod were selected. Lymphocytes level was analyzed at baseline and at months 1, 3, 6, 12, 18 and 24 after treatment starting. The number of relapses and infections was also collected at all timepoints.
Results: 99 patients were included in the study. 62.6% were women, the mean age was 39.8±7.56 years, with 9.6±5.8 years of disease evolution, 1.4±1.4 relapses in the previous year and a median EDSS of 2±1.68. The mean of lymphocytes was 2225±908, 849±379, 836±440, 774±392, 718±312, 662±222 and 693±264 respectively on baseline and on months 1, 3, 6, 12, 18 and 24. We found a correlation between severity of lymphopenia and basal lymphocytes during the first 18 months (Pearson 0.552, p< 0.001 (month 1); 0.470, p< 0.001 (month 3); 0.418, p< 0.001 (month 6), 0.336, p=0.003 (month 12); 0.333, p=0.021 (month 18); 0.070, p=0.663 (month 24). We did not found a direct correlation between levels of lymphocytes and infections (Pearson 0.076, p=0.470, month 3; 0.086, p=0.425, month 6; -0.032, p=0.783, month 12; -0.289, p=0.049, month 18; -0.090, p= 0.569, month 24) or relapses (Pearson -0.061, p=0.558, month 3; -0.041, p=0.704, month 6; 0.21, p=0.029, month 12; 0.068, p=0.644, month 18; 0.051, p=0.773, month 24).
Conclusions: Fingolimod causes a significant decrement in lymphocytes from the first month and it becomes maximal on month 18. The lymphopenia is higher in patients with lower levels of lymphocytes in baseline. The severity of lymphopenia is not related with infections or relapses.
Disclosure:
E Costa Arpín has served as a speaker and member of a speakers bureau for Biogen Idec Inc, Merck Serono, and Genzyme Corporation. She also has received grants for clinical research from H. Lundbeck A/S.
A Pato Pato has served as a speaker and member of a speakers bureau for Biogen Idec Inc, Novartis Pharmaceutical Corporation, Almirall Prodesfarma, and Genzyme Corporation.
A Rodríguez Regal has served as a speaker or member of a speakers bureau for Almirall Prodesfarma, Biogen Idec Inc, Merck Serono, Novartis Pharmaceuticals Corporation, and Teva Pharmaceuticals.
MC Amigo has served as a speaker or member of a speakers bureau for Almirall Prodesfarma, Biogen Idec Inc, Merck Serono, Novartis Pharmaceuticals Corporation, and Teva Pharmaceuticals.
J Prieto González has served as an advisor, consultant, and speaker for Bayer HealthCare Pharmaceuticals, Biogen Idec Inc, Genzyme Corporation, Novartis Pharmaceuticals Corporation, Sanofi Aventis, and Teva Pharmaceuticals. He has also received grants for clinical research from Biogen Idec Inc and Novartis Pharmaceuticals Corporation.